Navigation Links
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Date:5/15/2013

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2013 in Chicago, Illinois.  Both MEK inhibitors are expected to advance into Phase 3 trials in 2013:  Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma and Array expects to evaluate MEK162 in low-grade serous ovarian cancer.  In addition, AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib in non-small cell lung cancer and thyroid cancer. 

The following is a summary of the presentations that will be given at ASCO:  ORAL PRESENTATIONSTitle:Phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma (Abstract # CRA9003)Final results will be presented at ASCO.Presenter: Richard D. Carvajal, MDDate:Saturday, June 1, 2:15-2:30 p.m. CDT (Oral Presentation)Embargo:ASCO's embargo for this abstract will lift on Saturday, June 1 at 6:30 a.m. CDT.Press Conference ASCO will feature this study in the 2013 ASCO Annual Meeting press program on Saturday, June 1 from 8 – 9 a.m. CDT.Title: 

Phase II double-blind, randomized study of selumetinib plus dacarbazine versus placebo plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma (Abstract # 9004)Presenter: Mark R. Middleton, PhD, FRCPDate: 

Saturday, June 1, 2:30-2:45 p.m. CDT POSTER PRESENTATIONSTitle: Preliminary results from a Phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-depe
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
2. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
3. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Array BioPharma To Present At The Cowen Annual Health Care Conference
7. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
10. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
11. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... 15 Prometheus Laboratories Inc., a specialty pharmaceutical ... launch of three new cancer diagnostic products: ProOnc ... Dx. Each of these tests is based on ... has a long and successful history of providing ...
... Oct. 15 Aethlon Medical, Inc. (OTC Bulletin Board: ... treatment of Hepatitis-C (HCV) infected patients with the Aethlon ... & Scientific Exposition of the American Society of Nephrology ... studies and Director of Nephrology at the Fortis Hospital ...
Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3
(Date:8/22/2014)... UWDress.com, a leading online supplier of wedding dresses and women’s ... empire bridesmaid dresses to its product line. In addition ... these high quality items. All of them are now available ... , The company’s new items can definitely add beauty ... website. It is true that all its products are more ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Japantown ... offering a new teeth whitening technique. Air polishing is ... cleaning appointments. , Dark teeth can be caused by ... categories: external stains and internal stains. External stains include ... can be caused by certain medications, such as tetracycline, ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... to bring an end to the double–penalty system for health trusts ... a health trust falls into deficit, not only is it penalized ... money is cut off from its allocated funds from the ensuing ... health trusts find it virtually impossible to balance accounts and have ...
... Millions of Americans whose vision is slowly ebbing due to ... the lowly neural progenitor cell may be useful for restoring ... rats, neural progenitor cells derived from human fetal stem cells ... degenerative eye disease similar to the kinds of diseases that ...
... control high blood pressure and new drugs that target ... have designed two promising new cardiovascular treatment approaches, a ... to lower high blood pressure and a therapeutic hybrid ... ,In the process, they have overcome ...
... new study finds the popular anti-clotting drug clopidogrel (Plavix) when ... safe without any adverse bleeding event.// ,The ... 56th Annual Scientific Session on March 27 at 9 am ... aspirin, will not worsen bleeding after off-pump heart bypass surgery. ...
... multi-center study concludes that women with a recent diagnosis of ... opposite breast.// ,This study was conducted by ... ,The international research team found that MRI, or ... 30 of 969 women (3.1 percent) who had recently been ...
... considering vaccinating young girls against a virus that causes cervical ... Robert Koch-Institute in Germany has recommended the universal vaccination of ... ,The Italian Ministry of Health has announced that vaccination of ... as regional vaccination centers are prepared. ,Government ...
Cached Medicine News:Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Hormone-based Heart Pill to Control High Blood Pressure 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 3Health News:Plavix Safe During and After Heart Bypass 2Health News:MRI Screening of Other Breast Crucial for Patients Diagnosed With Cancer in One Breast 2
... Thermo Scientific Finnpipette Dispenser cover all volumes ... very high consistency, precision and reproducibility, due ... The Finnpipette Dispenser range is the latest ... manual liquid handling products, offering users reliability ...
... compact, mobile femtosecond surgical laser, has been ... for a wide spectrum of applications in ... demand of refractive surgeons for an "all-Laser ... efficient LASIK work-flow. The solution by Ziemer ...
... EHEC is the first one-step 20 minutes rapid ... and 2 produced by Enterohemorrhagic Escherichia coli in ... overnight enrichment of fecal specimens and detects all ... The separate result for Toxin 1 and 2 ...
Inquire...
Medicine Products: